Copenhagen - Delayed Quote DKK

Bavarian Nordic A/S (BAVA.CO)

201.60

-1.70

(-0.84%)

At close: January 10 at 4:59:57 PM GMT+1

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decision to launch the program is driven by a better-than-expected performance and improved visibility pertaining to the Company’s Travel Health business, with synergies from a number of recent and near-term expected events as described in the December 11 announcement. Bavarian Nordic will hold the shares

GlobeNewswire 2 days ago

BVNKF

BVNRY
Bavarian Nordic signs mpox vax deal with Serum Institute of India

The partnership aims to facilitate the vaccine's supply for the Indian market.

Pharmaceutical Technology 25 days ago

BAVA.CO
-0.84%
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India

Tech transfer of MVA-BN® will help increase global mpox vaccine manufacturing capacity and further expand the equitable access to vulnerable populations.Serum Institute of India obtains license to MVA-BN for the Indian market. COPENHAGEN, Denmark, December 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today a license and manufacturing agreement for its MVA-BN® mpox vaccine with Serum Institute of India Pvt. Ltd. (“SII”). Under the agreement, the companies will undertake a technology trans

GlobeNewswire 26 days ago

BVNKF

BVNRY
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NamePaul Chaplin2.Reason for the notification a)Position/status President and Chief Executive Officer of Bavarian Nordic A/S b

GlobeNewswire 29 days ago

BVNKF

BVNRY
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management and selected employees in the Bavarian Nordic Group. Members of the Executive Management are granted a mix of performance restricted stock units (Performance RSUs) and warrants, both subject to the successful achievement of relevant Key Performance Indicators (KPI’s). Employees participating in the

GlobeNewswire 29 days ago

BVNKF

BVNRY
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program

COPENHAGEN, Denmark, December 11, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a share buy-back program of up to DKK 150 million in the first quarter of 2025. This decision should be viewed in the context of improved visibility around the Company’s Travel Health business, driven by a number of completed and near-term expected events, including: A better-than-expected performance of the Travel Health business, as demonstrated by the recent guidance upgrade.The near-

GlobeNewswire last month

BVNKF

BVNRY
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 218,750 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 21,875 new shares were subscribed for in cash at DKK 146.60 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the capital

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic AS (BVNKF) Q3 2024 Earnings Call Highlights: Strong Travel Health Growth and ...

Bavarian Nordic AS (BVNKF) reports robust travel health business growth and strategic advancements in vaccine launches amid logistical challenges.

GuruFocus.com last month

BAVA.CO
-0.84%
Trump’s RFK Jr. Pick Weighs on Vaccine Makers

Kennedy, a vaccine skeptic, has promised sweeping changes to food and drug regulation and government-funded scientific research.

The Wall Street Journal last month

AZN

AZNCF

BNTX
Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.

Pharmaceutical Technology last month

BAVA.CO
-0.84%
US expected to increase biodefence spending under Trump, says vaccine maker Bavarian Nordic

COPENHAGEN (Reuters) -Vaccine maker Bavarian Nordic expects the incoming Trump administration to boost biodefence funding despite the nomination of Robert F. Kennedy Jr., a vaccine sceptic, as health secretary, the company's CEO said on Friday. Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump selected Kennedy, who has previously spread misinformation on vaccines, to lead the top health agency. "Vaccine scepticism was part of Trump's first administration," Bavarian Nordic CEO Paul Chaplin told Reuters in an interview.

Reuters last month

BAVA.CO
-0.84%
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Shares in European vaccine makers tumbled after President-elect Donald Trump picked vaccine sceptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

The Wall Street Journal last month

INRLF

VALN

BVNKF
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024

COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024. Revenue for the first nine months was DKK 3,622 million, and the operating profit (EBITDA) was DKK 692 million.Revenue from Travel Health increased by 18% to DKK 1,892 million compared to the first nine months of 2023 and revenue from Public Preparedness was DKK 1,549 million, which is in line

GlobeNewswire last month

BVNKF

BVNRY
Is Bavarian Nordic (BVNRY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

BAVA.CO
-0.84%
Bavarian Nordic’s mpox vaccine to be trialled in pregnant women and infants

Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Clinical Trials Arena 2 months ago

BAVA.CO
-0.84%
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Zacks 2 months ago

BAVA.CO
-0.84%
DARE
Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial

The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children between two and 11 years of age.

Clinical Trials Arena 2 months ago

BAVA.CO
-0.84%
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age. COPENHAGEN, Denmark, October 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age. The first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to include sites i

GlobeNewswire 2 months ago

BVNKF

BVNRY
Is Bavarian Nordic (BVNRY) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 2 months ago

BAVA.CO
-0.84%
Bavarian Nordic’s mpox vaccine equally effective in teens as adults

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

Clinical Trials Arena 2 months ago

BAVA.CO
-0.84%

Performance Overview

Return	BAVA.CO	^OMXC25,142360,17094500
YTD	+6.47%	+1.64%
1-Year	+15.66%	-2.78%
3-Year	-17.17%	-3.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bavarian Nordic A/S (BAVA.CO)

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

Bavarian Nordic signs mpox vax deal with Serum Institute of India

Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Bavarian Nordic AS (BVNKF) Q3 2024 Earnings Call Highlights: Strong Travel Health Growth and ...

Trump’s RFK Jr. Pick Weighs on Vaccine Makers

Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

US expected to increase biodefence spending under Trump, says vaccine maker Bavarian Nordic

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Bavarian Nordic Announces Interim Results for the First Nine Months of 2024

Is Bavarian Nordic (BVNRY) Stock Undervalued Right Now?

Bavarian Nordic’s mpox vaccine to be trialled in pregnant women and infants

Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?

Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine

Is Bavarian Nordic (BVNRY) a Great Value Stock Right Now?

Bavarian Nordic’s mpox vaccine equally effective in teens as adults

Performance Overview